Adriana V. Treuer

Dr. Adriana V. Treuer

University of Talca, Talca, Maule, Chile
orcid
Senior Researcher at Universidad de Talca

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
Daniel GonzalezDaniel Gonzalez
Daniel Gonzalez
FBFarideh Beigi
Farideh Beigi
Adriana V. TreuerAdriana V. Treuer
Adriana V. Treuer
JHJoshua M. Hare
Joshua M. Hare
Altered Ca 2+ homeostasis is a salient feature of heart disease, where the calcium release channel ryanodine receptor (RyR) plays a major role. Accumulating data support the notion that neuronal nitric oxide synthase (NOS1) regulates the cardiac RyR via S -nitrosylation. We tested the hypothesis that NOS1 deficiency impairs RyR S -nitrosylation, leading to altered Ca 2+ homeostasis. Diastolic Ca 2+ levels are elevated in NOS1 −/− and NOS1/NOS3 −/− but not NOS3 −/− myocytes compared with wild-type (WT), suggesting diastolic Ca 2+ leakage. Measured leak was increased in NOS1 −/− and NOS1/NOS3 −/− but not in NOS3 −/− myocytes compared with WT. Importantly, NOS1 −/− and NOS1/NOS3 −/− myocytes also exhibited spontaneous calcium waves. Whereas the stoichiometry and binding of FK-binding protein 12.6 to RyR and the degree of RyR phosphorylation were not altered in NOS1 −/− hearts, RyR2 S -nitrosylation was substantially decreased, and the level of thiol oxidation increased. Together, these findings demonstrate that NOS1 deficiency causes RyR2 hyponitrosylation, leading to diastolic Ca 2+ leak and a proarrhythmic phenotype. NOS1 dysregulation may be a proximate cause of key phenotypes associated with heart disease.

1 September 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
Daniel GonzalezDaniel Gonzalez
Daniel Gonzalez
Adriana V. TreuerAdriana V. Treuer
Adriana V. Treuer
JCJorge Castellanos
Jorge Castellanos
RDRaul A. Dulce
Raul A. Dulce
JHJoshua M. Hare
Joshua M. Hare
S-Nitrosylation is a ubiquitous post-translational modification that regulates diverse biologic processes. In skeletal muscle, hypernitrosylation of the ryanodine receptor (RyR) causes sarcoplasmic reticulum (SR) calcium leak, but whether abnormalities of cardiac RyR nitrosylation contribute to dysfunction of cardiac excitation-contraction coupling remains controversial. In this study, we tested the hypothesis that cardiac RyR2 is hyponitrosylated in heart failure, because of nitroso-redox imbalance. We evaluated excitation-contraction coupling and nitroso-redox balance in spontaneously hypertensive heart failure rats with dilated cardiomyopathy and age-matched Wistar-Kyoto rats. Spontaneously hypertensive heart failure myocytes were characterized by depressed contractility, increased diastolic Ca(2+) leak, hyponitrosylation of RyR2, and enhanced xanthine oxidase derived superoxide. Global S-nitrosylation was decreased in failing hearts compared with nonfailing. Xanthine oxidase inhibition restored global and RyR2 nitrosylation and reversed the diastolic SR Ca(2+) leak, improving Ca(2+) handling and contractility. Together these findings demonstrate that nitroso-redox imbalance causes RyR2 oxidation, hyponitrosylation, and SR Ca(2+) leak, a hallmark of cardiac dysfunction. The reversal of this phenotype by inhibition of xanthine oxidase has important pathophysiologic and therapeutic implications.

24 February 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
FBFarideh Beigi
Farideh Beigi
Daniel GonzalezDaniel Gonzalez
Daniel Gonzalez
KMKhalid M. Minhas
Khalid M. Minhas
QSQi-An Sun
Qi-An Sun
MFMatthew W. Foster
Matthew W. Foster
JHJoshua M. Hare
Joshua M. Hare
Although protein S -nitrosylation is increasingly recognized as mediating nitric oxide (NO) signaling, roles for protein denitrosylation in physiology remain unknown. Here, we show that S -nitrosoglutathione reductase (GSNOR), an enzyme that governs levels of S -nitrosylation by promoting protein denitrosylation, regulates both peripheral vascular tone and β-adrenergic agonist-stimulated cardiac contractility, previously ascribed exclusively to NO/cGMP. GSNOR-deficient mice exhibited reduced peripheral vascular tone and depressed β-adrenergic inotropic responses that were associated with impaired β-agonist–induced denitrosylation of cardiac ryanodine receptor 2 (RyR2), resulting in calcium leak. These results indicate that systemic hemodynamic responses (vascular tone and cardiac contractility), both under basal conditions and after adrenergic activation, are regulated through concerted actions of NO synthase/GSNOR and that aberrant denitrosylation impairs cardiovascular function. Our findings support the notion that dynamic S -nitrosylation/denitrosylation reactions are essential in cardiovascular regulation.

1 September 2009 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
Daniel GonzalezDaniel Gonzalez
Daniel Gonzalez
Adriana V. TreuerAdriana V. Treuer
Adriana V. Treuer
QSQi-An Sun
Qi-An Sun
JSJonathan S Stamler
Jonathan S Stamler
JHJoshua M. Hare
Joshua M. Hare
Nitric oxide (NO) exerts ubiquitous signaling via posttranslational modification of cysteine residues, a reaction termed S-nitrosylation. Important substrates of S-nitrosylation that influence cardiac function include receptors, enzymes, ion channels, transcription factors, and structural proteins. Cardiac ion channels subserving excitation-contraction coupling are potentially regulated by S-nitrosylation. Specificity is achieved in part by spatial colocalization of ion channels with nitric oxide synthases (NOSs), enzymatic sources of NO in biologic systems, and by coupling of NOS activity to localized calcium/second messenger concentrations. Ion channels regulate cardiac excitability and contractility in millisecond timescales, raising the possibility that NO-related species modulate heart function on a beat-to-beat basis. This review focuses on recent advances in understanding of NO regulation of the cardiac action potential and of the calcium release channel ryanodine receptor, which is crucial for the generation of force. S-Nitrosylation signaling is disrupted in pathological states in which the redox state of the cell is dysregulated, including ischemia, heart failure, and atrial fibrillationS.

21 January 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
RKRosemeire M. Kanashiro-Takeuchi
Rosemeire M. Kanashiro-Takeuchi
KTKonstantinos Tziomalos
Konstantinos Tziomalos
LTLauro M. Takeuchi
Lauro M. Takeuchi
Adriana V. TreuerAdriana V. Treuer
Adriana V. Treuer
GLGuillaume Lamirault
Guillaume Lamirault
JHJoshua M. Hare
Joshua M. Hare
Whether the growth hormone (GH)/insulin-like growth factor 1(IGF-1) axis exerts cardioprotective effects remains controversial; and the underlying mechanism(s) for such actions are unclear. Here we tested the hypothesis that growth hormone-releasing hormone (GHRH) directly activates cellular reparative mechanisms within the injured heart, in a GH/IGF-1 independent fashion. After experimental myocardial infarction (MI), rats were randomly assigned to receive, during a 4-week period, either placebo (n = 14), rat recombinant GH (n = 8) or JI-38 (n = 8; 50 µg/kg per day), a potent GHRH agonist. JI-38 did not elevate serum levels of GH or IGF-1, but it markedly attenuated the degree of cardiac functional decline and remodeling after injury. In contrast, GH administration markedly elevated body weight, heart weight, and circulating GH and IGF-1, but it did not offset the decline in cardiac structure and function. Whereas both JI-38 and GH augmented levels of cardiac precursor cell proliferation, only JI-38 increased antiapoptotic gene expression. The receptor for GHRH was detectable on myocytes, supporting direct activation of cardiac signal transduction. Collectively, these findings demonstrate that within the heart, GHRH agonists can activate cardiac repair after MI, suggesting the existence of a potential signaling pathway based on GHRH in the heart. The phenotypic profile of the response to a potent GHRH agonist has therapeutic implications.

1 February 2012 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
BOBehzad N. Oskouei
Behzad N. Oskouei
GLGuillaume Lamirault
Guillaume Lamirault
CJChacko Joseph
Chacko Joseph
Adriana V. TreuerAdriana V. Treuer
Adriana V. Treuer
SLStephanie Landa
Stephanie Landa
JHJoshua M. Hare
Joshua M. Hare
Whereas cardiac-derived c-kit+ stem cells (CSCs) and bone marrow-derived mesenchymal stem cells (MSCs) are undergoing clinical trials testing safety and efficacy as a cell-based therapy, the relative therapeutic and biologic efficacy of these two cell types is unknown. We hypothesized that human CSCs have greater ability than MSCs to engraft, differentiate, and improve cardiac function. We compared intramyocardial injection of human fetal CSCs (36,000) with two doses of adult MSCs (36,000 and 1,000,000) or control (phosphate buffered saline) in nonobese diabetic/severe combined immune deficiency mice after coronary artery ligation. The myocardial infarction-induced enlargement in left ventricular chamber dimensions was ameliorated by CSCs (p < .05 for diastolic and systolic volumes), as was the decline in ejection fraction (EF; p < .05). Whereas 1 × 106 MSCs partially ameliorated ventricular remodeling and improved EF to a similar degree as CSCs, 36,000 MSCs did not influence chamber architecture or function. All cell therapies improved myocardial contractility, but CSCs preferentially reduced scar size and reduced vascular afterload. Engraftment and trilineage differentiation was substantially greater with CSCs than with MSCs. Adult-cultured c-kit+CSCs were less effective than fetal, but were still more potent than high-dose MSCs. These data demonstrate enhanced CSC engraftment, differentiation, and improved cardiac remodeling and function in ischemic heart failure. MSCs required a 30-fold greater dose than CSCs to improve cardiac function and anatomy. Together, these findings demonstrate a greater potency of CSCs than bone marrow MSCs in cardiac repair.